Advertisement

 

 

Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients.

Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients.
Author Information (click to view)

Wang JY, Peng SH, Ning XH, Li T, Liu SJ, Liu JY, Hong BA, Qi NN, Peng X, Zhou BW, Zhang JF, Cai L, Gong K,


Wang JY, Peng SH, Ning XH, Li T, Liu SJ, Liu JY, Hong BA, Qi NN, Peng X, Zhou BW, Zhang JF, Cai L, Gong K, (click to view)

Wang JY, Peng SH, Ning XH, Li T, Liu SJ, Liu JY, Hong BA, Qi NN, Peng X, Zhou BW, Zhang JF, Cai L, Gong K,

Advertisement

Cancer medicine 2017 08 04() doi 10.1002/cam4.1134
Abstract

Von Hippel-Lindau (VHL) disease is a rare autosomal dominant cancer syndrome caused by alterations of VHL gene. Patients are predisposed to develop pheochromocytomas and solid or cystic tumors of the central nervous system, kidney, pancreas, and retina. Remarkable phenotypic heterogeneity exits in organ involvement and tumor onset age between and within VHL families. However, no reliable markers have been found to predict the age-related tumor risks in VHL patients. A large Chinese cohort composed of 300 VHL patients and 92 healthy family controls was enrolled in our study. Blood relative telomere length was measured in 184 patients and all the controls available for genomic DNA samples. Age-related risks for the five major VHL-associated tumors were evaluated using Kaplan-Meier plots and Cox regression analysis. Differences in clinical phenotype were observed between Chinese cohort and the United Kingdom cohort. VHL patients showed significantly shorter telomere length than healthy family controls(P = 0.0183), and a positive correlation was found between telomere length and onset age of the five major tumors, respectively. Moreover, patients in the shorter telomere group (age-adjusted telomere length ≤ 0.44) suffered higher age-related risks for VHL-associated central nervous system hemangioblastomas (HR: 1.879, P = 0.004), renal cell carcinoma (HR: 2.126, P = 0.002) and pancreatic cyst and neuroendocrine tumors (HR: 2.093, P = 0.001). These results indicate that blood shorter telomere length is a new biomarker for age-related tumor risks in VHL patients, which will be crucial to genetic counseling and future research about the role of telomere shortening in the pathogenesis of VHL-associated tumors.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen − eighteen =

[ HIDE/SHOW ]